18:55 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Feb. 1, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I...
21:12 , Feb 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I diabetes....
00:47 , Feb 1, 2019 |  BC Week In Review  |  Company News

AbbVie loses $8B in market cap on steeper Humira erosion

AbbVie Inc. (NYSE:ABBV) lost $5.34 to $80.54 on Jan. 25, representing a loss of almost $8 billion in market cap, after announcing it expects a higher rate of erosion in ex-U.S. sales on autoimmune drug...
22:32 , Jan 25, 2019 |  BC Extra  |  Company News

AbbVie loses $8B in market cap on steeper Humira erosion

AbbVie Inc. (NYSE:ABBV) lost $5.34 to $80.54 on Friday, representing a loss of almost $8 billion in market cap, after announcing it expects a higher rate of erosion in ex-U.S. sales on autoimmune drug Humira...
23:55 , Jan 2, 2019 |  BC Extra  |  Politics & Policy

Part D beneficiaries hit hardest under 2019 price hikes

Drug price increases announced beginning Jan. 1 will disproportionately affect Medicare Part D beneficiaries, reinforcing a practice the Trump administration has sought to curb. Data from Evercore ISI Research on 13 pharmaceutical and biotech companies...
22:56 , Dec 17, 2018 |  BioCentury  |  Politics, Policy & Law

When drugs can’t go generic: Honoring our end of the contract with 'synthetic genericization'

The biopharma industry’s social contract with society relies on the idea that drugs eventually go generic and thereafter remain inexpensive. When that can’t happen, the contract breaks down - but there are ways to fix...
18:26 , Nov 30, 2018 |  BC Week In Review  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
00:02 , Nov 29, 2018 |  BC Extra  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
16:05 , Nov 16, 2018 |  BC Week In Review  |  Company News

California sues AbbVie over alleged Humira kickbacks

California Insurance Commissioner Dave Jones filed a lawsuit Sept. 18 accusing AbbVie Inc. (NYSE:ABBV) of "systematically and repeatedly" violating the Insurance Frauds Prevention Act by providing kickbacks to healthcare providers throughout California. According to the...
18:20 , Nov 9, 2018 |  BC Week In Review  |  Company News

AbbVie says global Humira market eroding faster than expected

AbbVie Inc. (NYSE:ABBV) Chairman and CEO Richard Gonzalez said the company now expects greater erosion in ex-U.S. sales of autoimmune drug Humira adalimumab by the end of next year than previously guided. During the pharma’s...